Opioid Damages and Health Care Costs Recovery Act, 2023, c.28

Section 1

Definitions and interpretation

Cite as Opioid Damages and Health Care Costs Recovery Act, 2023, c.28, s. 1 · current to December 13, 2023 · read from New Brunswick Acts and Regulations on November 16, 2026

The text

(1) The following definitions apply in this Act. “consultant” means a person who provides advisory services (conseiller) (a) to a wholesaler in relation to the distribution, sale or offering for sale of opioid products, or (b) to a manufacturer in relation to the sale of opioid products. “cost of health care benefits” means the sum of (coût des services de soins de santé) (a) the present value of the total expenditure by the Crown in right of the Province for health care benefits provided for insured persons as a result of opioid-related disease, injury or illness or the risk of opioid-related disease, injury or illness, and (b) the present value of the estimated total expenditure by the Crown in right of the Province for health care benefits that could reasonably be expected to be provided for those insured persons as a result of opioid-related disease, injury or illness or the risk of opioid-related disease, injury or illness. “disease, injury or illness” includes problematic substance use, addiction and general deterioration of health. (maladie, blessure ou affection) “health care benefits” means (services de soins de santé) (a) entitled services as defined in the Medical Services Payment Act, (b) entitled services as defined in the Hospital Services Act, (c) goods or services provided or payments made by the Crown in right of the Province under the Ambulance Services Act, the Prescription Drug Payment Act, the Prescription and Catastrophic Drug Insurance Act, the Health Services Act, the Family Services Act, the Child and Youth Well-Being Act, the Nursing Homes Act and the Public Health Act, and (d) other expenditures by the Crown in right of the Province, made directly or through one or more agents or other intermediate bodies, for programs, services, benefits or similar matters associated with disease, injury or illness. “health care provider” means a person who (fournisseur de soins de santé) (a) is a regulated health professional authorized by an Act to prescribe or advise on the therapeutic value, contents and hazards of a drug, and (b) is not prohibited from prescribing a drug that is an opioid product. “insured person” means (assuré) (a) a person, including a deceased person, for whom health care benefits have been provided, or (b) a person for whom health care benefits could reasonably be expected to be provided. “joint venture” means an association of two or more persons, if (coentreprise) (a) the relationship among the persons does not constitute a corporation, partnership or trust, and (b) the persons each have an undivided interest in assets of the association. “manufacture” includes, for an opioid product, the production, assembly and packaging of the opioid product. (fabrication) “manufacturer” means a person who manufactures or has manufactured an opioid product and a person who, in the past or currently, (fabricant) (a) causes, directly or indirectly, through arrangements with contractors, subcontractors, licensees, franchisees or others, the manufacture of an opioid product, (b) for any fiscal year of the person, derives at least 10% of revenues, determined on a consolidated basis in accordance with generally accepted accounting principles in Canada, from the manufacture or promotion of opioid products by that person or by other persons, (c) engages in or causes, directly or indirectly, other persons to engage in promoting an opioid product, or (d) is a trade association primarily engaged in (i) advancing the interests of manufacturers, (ii) promoting an opioid product, or (iii) causing, directly or indirectly, other persons to engage in promoting an opioid product. “opioid product” means an active ingredient or drug set out in Schedule A or prescribed by regulation or a product that contains one of those active ingredients or drugs. (produit opioïde) “opioid-related disease, injury or illness” means disease, injury or illness caused or contributed to by an individual’s use of or exposure to an opioid product, whether the opioid product is (maladie, blessure ou affection liée aux opioïdes) (a) in the form in which it was manufactured, (b) combined with another drug or substance, or (c) used or, in the case of exposure, is present in a form or manner other than (i) as prescribed or advised by a health care provider, or (ii) as recommended by the manufacturer of that opioid product. “opioid-related wrong” means (faute liée aux opioïdes) (a) a tort that is committed in the Province by a manufacturer, wholesaler or consultant that causes or contributes to opioid-related disease, injury or illness, or (b) in an action under subsection 2(1), a breach, by a manufacturer, wholesaler or consultant, of a common law, equitable or statutory duty or obligation owed to persons in the Province who have used or been exposed to or might use or be exposed to an opioid product. “person” includes a trust, joint venture or trade association. (personne) “promote” or “promotion” includes, for an opioid product, (promotion) or (promouvoir) (a) the marketing of the opioid product, whether direct or indirect, (b) the distribution or sale of the opioid product, and (c) any research with respect to the opioid product. “type of opioid product” means an opioid product in the form of a pill, a capsule, an oral liquid, a powder, an injectable, a topical or a combination of any of these. (type de produit opioïde) “use” or “exposure” , in relation to an opioid product, means ingestion, inhalation, injection, application or assimilation of the opioid product, whether intentional or otherwise. (consommation) or (exposition) “wholesaler” means a person who distributes, sells or offers for sale opioid products to (grossiste) (a) pharmacies, distributors or other persons for resale, or (b) hospitals, facilities or care centres for patient use. (2) The definition “manufacturer” in subsection (1) does not include (a) an individual, (b) a wholesaler or retailer of opioid products who is not related to (i) a person who manufactures an opioid product, or (ii) a person described in paragraph (a) of the definition “manufacturer”, or (c) a person who (i) is a manufacturer only because paragraph (b) or (c) of the definition “manufacturer” applies to the person, and (ii) is not related to (A) a person who manufactures an opioid product, or (B) a person described in paragraph (a) or (d) of the definition “manufacturer”. (3) For the purposes of subsection (2), a person is related to another person if, directly or indirectly, the person is (a) an affiliate, as defined in Business Corporations Act, of the other person, or (b) an affiliate of the other person or an affiliate of an affiliate of the other person. (4) For the purposes of paragraph (3)(b), a person is deemed to be an affiliate of another person if the person (a) is a corporation and the other person, or a group of persons not dealing with each other at arm’s length of which the other person is a member, owns a beneficial interest in shares of the corporation (i) carrying at least 50% of the votes for the election of directors of the corporation, and the votes carried by the shares are sufficient, if exercised, to elect a director of the corporation, or (ii) having a fair market value, including a premium for control, if applicable, of at least 50% of the fair market value of all the issued and outstanding shares of the corporation, or (b) is a partnership, trust or joint venture, and the other person, or a group of persons not dealing with each other at arm’s length of which the other person is a member, has an ownership interest in the assets of that person that entitles the other person or group of persons to receive at least 50% of the profits or at least 50% of the assets on the dissolution, winding-up or termination of the partnership, trust or joint venture. (5) For the purposes of paragraph (3)(b), a person is deemed to be an affiliate of another person if the other person, or a group of persons not dealing with each other at arm’s length of which the other person is a member, has any direct or indirect influence that, if exercised, would result in control in fact of that person, except if the other person or group of persons deals at arm’s length with that person and derives influence solely as a lender. (6) For the purposes of determining the market share of a manufacturer for a type of opioid product sold in the Province, the court shall calculate the manufacturer’s market share for the type of opioid product by the following formula: mms = mm/MM x 100% where in this formula, mms is the manufacturer’s market share for the type of opioid product from the date of the earliest opioid-related wrong committed by that manufacturer to the date of trial, mm is the quantity of the type of opioid product manufactured by the manufacturer that is distributed, sold or offered for sale in the Province from the date of the earliest opioid-related wrong committed by that manufacturer to the date of trial, and MM is the quantity of the type of opioid product manufactured by all manufacturers that is purchased or dispensed in the Province for the purpose of providing health care benefits from the date of the earliest opioid-related wrong committed by the manufacturer to the date of trial. (7) For the purposes of determining the market share of a wholesaler for a type of opioid product sold in the Province, the court shall calculate the wholesaler’s market share for the type of opioid product by the following formula: wms = wm/WM x 100% where in this formula, wms is the wholesaler’s market share for the type of opioid product from the date of the earliest opioid-related wrong committed by that wholesaler to the date of trial, wm is the quantity of the type of opioid product that is distributed, sold or offered for sale by the wholesaler in the Province from the date of the earliest opioid-related wrong committed by that wholesaler to the date of trial, and WM is the quantity of the type of opioid product that is distributed, sold or offered for sale by all wholesalers in the Province for the purpose of providing health care benefits from the date of the earliest opioid-related wrong committed by the wholesaler to the date of trial.
Read the Opioid Damages and Health Care Costs Recovery Act on the Province's website ↗